These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 8585734)

  • 1. Comparison of the bactericidal activities of ofloxacin and ciprofloxacin alone and in combination with ceftazidime and piperacillin against clinical strains of Pseudomonas aeruginosa.
    Klepser ME; Patel KB; Nicolau DP; Quintiliani R; Nightingale CH
    Antimicrob Agents Chemother; 1995 Nov; 39(11):2503-10. PubMed ID: 8585734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro synergy testing of levofloxacin, ofloxacin, and ciprofloxacin in combination with aztreonam, ceftazidime, or piperacillin against Pseudomonas aeruginosa.
    Pendland SL; Messick CR; Jung R
    Diagn Microbiol Infect Dis; 2002 Jan; 42(1):75-8. PubMed ID: 11821176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the bactericidal activity of trovafloxacin and ciprofloxacin, alone and in combination with cefepime, against Pseudomonas aeruginosa.
    McNabb J; Quintiliani R; Nightingale CH; Nicolau DP
    Chemotherapy; 2000; 46(6):383-9. PubMed ID: 11053903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model.
    Cappelletty DM; Kang SL; Palmer SM; Rybak MJ
    Antimicrob Agents Chemother; 1995 Aug; 39(8):1797-801. PubMed ID: 7486921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the bactericidal activities of piperacillin-tazobactam, ticarcillin-clavulanate, and ampicillin-sulbactam against clinical isolates of Bacteroides fragilis, Enterococcus faecalis, Escherichia coli, and Pseudomonas aeruginosa.
    Klepser ME; Marangos MN; Zhu Z; Nicolau DP; Quintiliani R; Nightingale CH
    Antimicrob Agents Chemother; 1997 Feb; 41(2):435-9. PubMed ID: 9021203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model.
    Kang SL; Rybak MJ; McGrath BJ; Kaatz GW; Seo SM
    Antimicrob Agents Chemother; 1994 Dec; 38(12):2702-9. PubMed ID: 7695250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cefepime, piperacillin/tazobactam, gentamicin, ciprofloxacin, and levofloxacin alone and in combination against Pseudomonas aeruginosa.
    Burgess DS; Nathisuwan S
    Diagn Microbiol Infect Dis; 2002 Sep; 44(1):35-41. PubMed ID: 12376029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once versus thrice daily tobramycin alone and in combination with ceftazidime, ciprofloxacin and imipenem in an in vitro pharmacodynamic model.
    Zelenitsky SA; Karlowsky JA; Hoban DJ; Kabani A; Zhanel GG
    Chemotherapy; 1998; 44(1):1-6. PubMed ID: 9444401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum bactericidal activity of ceftazidime: continuous infusion versus intermittent injections.
    Nicolau DP; Nightingale CH; Banevicius MA; Fu Q; Quintiliani R
    Antimicrob Agents Chemother; 1996 Jan; 40(1):61-4. PubMed ID: 8787880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibiotic dosing issues in lower respiratory tract infection: population-derived area under inhibitory curve is predictive of efficacy.
    Highet VS; Forrest A; Ballow CH; Schentag JJ
    J Antimicrob Chemother; 1999 Mar; 43 Suppl A():55-63. PubMed ID: 10225573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals.
    Ludwig E; Konkoly-Thege M; Kuti JL; Nicolau DP
    Int J Antimicrob Agents; 2006 Nov; 28(5):433-8. PubMed ID: 17046212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro efficacy of levofloxacin alone or in combination tested against multi-resistant Pseudomonas aeruginosa strains.
    Flynn CM; Johnson DM; Jones RN
    J Chemother; 1996 Dec; 8(6):411-5. PubMed ID: 8981179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosing.
    Burgess DS; Waldrep T
    Clin Ther; 2002 Jul; 24(7):1090-104. PubMed ID: 12182254
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Goodlet KJ; Nicolau DP; Nailor MD
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of piperacillin/tazobactam in combination with amikacin, ciprofloxacin, and trovafloxacin against Pseudomonas aeruginosa by time-kill.
    Burgess DS; Hastings RW
    Diagn Microbiol Infect Dis; 2000 Sep; 38(1):37-41. PubMed ID: 11025182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pseudomonas aeruginosa: bactericidal activity on various beta-lactam resistance phenotypes of 8 antibiotics and 7 combinations].
    Dubrous P; Cavallo JD; Hernandez E; Nordmann P; Fabre R
    Pathol Biol (Paris); 1997 May; 45(5):433-7. PubMed ID: 9296099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and pharmacodynamics of two multiple-dose piperacillin-tazobactam regimens.
    Occhipinti DJ; Pendland SL; Schoonover LL; Rypins EB; Danziger LH; Rodvold KA
    Antimicrob Agents Chemother; 1997 Nov; 41(11):2511-7. PubMed ID: 9371358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Geographic variations in activity of broad-spectrum beta-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997-2000).
    Jones RN; Kirby JT; Beach ML; Biedenbach DJ; Pfaller MA
    Diagn Microbiol Infect Dis; 2002 Jul; 43(3):239-43. PubMed ID: 12106958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections.
    Benko AS; Cappelletty DM; Kruse JA; Rybak MJ
    Antimicrob Agents Chemother; 1996 Mar; 40(3):691-5. PubMed ID: 8851594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-antibiotic and synergic effects of fluoroquinolones and ceftazidime in combination against Pseudomonas strains.
    Mayer I; Nagy E
    Acta Biol Hung; 2001; 52(2-3):241-8. PubMed ID: 11426858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.